Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Q2 2022 Earnings Presentation
11 slides from Fresenius Medical Care's earnings presentation, Jul 28, 2022
Slide 1: Conference Call Preliminary Q2 2022
Conference Call Preliminary Q2 2022 July 28, 2022 Helen Giza Deputy Chief Executive Officer & Chief Financial Officer © Copyright
Slide 2: Safe harbor statement
Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncert
Slide 3: Q2 2022 | Macro conditions burden business development
Q2 2022 | Macro conditions burden business development • Unprecedented U.S. labor market Key Figures situation constraining capacity and (preliminary, unaudited) accelerating wage inflation • Worsening macroeconomic environment Q2 2022 Q2 2021 Growth Growth € million € million in % in %cc driving co
Slide 4: FY 2022 | YTD development vs. previously assumed Head-/Tailwinds
FY 2022 | YTD development vs. previously assumed Head-/Tailwinds Impact on operating income (€m) Labor cost increase beyond 3% net 100 of U.S. Provider Relief Fund Macroeconomic inflationary environment 50 107 and elevated supply chain costs 100 58 COVID-19-related excess mortality Headwinds U.S. ba
Slide 5: Q2 2022 | Revenue supported by favorable exchange rate
Q2 2022 | Revenue supported by favorable exchange rate (preliminary, unaudited) HEALTH CARE PRODUCTS HEALTH CARE SERVICES Revenue: €3,782m Revenue: €975m +11% | +1% cc | 0% organic +6% | +1% cc | +1% organic ▪ Negative organic growth in North America, offset ▪ Stable contribution mainly driven by hi
Slide 6: Q2 2022 | Operating income margin development
Q2 2022 | Operating income margin development (preliminary, unaudited) 9.8% 0pp (2.1pp) 0.4pp 9.4% (1.6pp) 3.2pp (1.7p) (0.3pp) (0.3pp) 7.2% (0.2pp) Q2 2021 Business Inflation and Labor cost Ballot Governmental FME25 Q2 2022 Humacyte FME25 Hyperinflation Q2 2022 operating growth, incl. supply chain
Slide 7: FY 2022 | New expectations for Tail- & Headwinds
FY 2022 | New expectations for Tail- & Headwinds Previous Expected negative impact on operating income (€M) assumption Macro-economic inflationary environment ~ € 50M 220 and elevated supply chain costs ~ € 100M 100 COVID-19-related excess mortality ~ € 100M 100 Labor cost increase beyond 3% net Hea
Slide 8: FY 2022 Guidance | Mid-term outlook
FY 2022 Guidance | Mid-term outlook Excluding special items: REVENUE NET INCOME Special items include costs related to FME25, the Ukraine war, hyper- FY2022 FY2022 inflation accounting in Turkiye, the Humacyte investment remeasurement and other effects that are unusual in nature and have not been fo
Slide 9: Advancing on our strategic priorities
Advancing on our strategic priorities Home Value-based care Sustainability FME25 ▪ New aspirational ▪ Improve clinical ▪ Focus on global ▪ New global operating target: 25% by 2025 outcomes and quality of sustainability program, model with two ▪ Home treatments still life for patients with including
Slide 10: FME25 program timeline and initiatives
FME25 program timeline and initiatives FME25 framework 2022 key achievements & next steps Overall 2021 Alignment of new operating model Two levels of leadership & organizational structure announced ▪ Transition journey defined & first initiatives started Remapping operational activities to future st
Slide 11: Your questions are welcome.
Your questions are welcome. © Copyright
Fresenius Medical Care — Q2 2022 Earnings Presentation on 6ix